CD274 and non-small cell lung carcinoma: More than 1,000 clinical trials have demonstrated extensive clinical benefits from the immune checkpoint blockade (ICB) therapy targeting the PD-1/PD-L1 axis, which has been approved to treat diverse advanced malignancies including melanoma2, non-small cell lung cancer (NSCLC)3, microsatellite instable-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer4.